Sumitomo Pharma Co., Ltd.

Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia
Business Wire · 26 Oct 2026
Certain Common Stock of Sumitomo Pharma Co., Ltd. are subject to a Lock-Up Agreement Ending on 24-OCT-2026.
www.marketscreener.com · 24 Oct 2026
Sumitomo Pharma Co.Ltd. Estimates – TSE:4506
TradingView · 23 Oct 2026
Sumitomo Pharma (TSE:4506) Reports 29% TWYMEEG Sales Growth, Is The Discount Still Meaningful?
Simply Wall Street · 20 Oct 2026
Yomiuri: Sumitomo Pharma Eyes U.S. Ties for Smooth Adoption of iPS Cell Parkinson's Treatment
MarketWatch · 14 Oct 2026

Headlines from the last 30 days, linking to the original publishers. See all market news →

Disclaimer — PositoAI is a research and screening tool for educational and informational purposes. It is not investment advice or a recommendation to buy or sell any security or mutual fund. Scores and rankings are calculated by PositoAI's own method using publicly available data, which may be incomplete, delayed or inaccurate, and past performance does not indicate future results. AI summaries of company news may contain errors. PositoAI is not registered with the SEC, SEBI or any other regulatory authority. Please do your own research or consult a licensed financial advisor before investing.